Browse the evidence

Orforglipron has advanced through Phase 3 clinical development, demonstrating significant reductions in hemoglobin A1c and body weight (up to 7.9%) with favorable tolerability.

Practitioners can consider Orforglipron as an effective option for managing hemoglobin A1c and body weight.

Novel incretin-based therapies have gained popularity due to their effectiveness in achieving substantial weight loss.

Healthcare providers should consider incretin-based therapies as effective options for weight management.

GLP-1 receptor agonists (GLP-1RAs) and dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonists (GLP-1/GIPRA) significantly reduce body weight and adiposity.

Practitioners can expect significant weight loss and reduction in adiposity with GLP-1RA and GLP-1/GIPRA therapies.

Correcting hormonal deficiencies may improve exercise capacity and reduce major cardiac events.

Clinicians should consider hormonal assessments in patients at risk of cardiovascular events.

Patients in the clinical pharmacist cohort achieved a mean body weight reduction of 9.32% compared to 5.11% body weight reduction for patients in the primary care physician cohort.

Incorporating clinical pharmacists in weight management can lead to greater weight loss outcomes.

The use of long‐acting incretin‐based therapies, such as semaglutide, has increased due to their benefits for glycemic control in diabetes, cardiovascular risk reduction, and weight management.

Clinicians should consider the benefits of semaglutide for patients with diabetes and weight management needs.

Retatrutide exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM).

Retatrutide may be an effective treatment option for managing HbA1c and weight in T2DM patients.

In non-T2DM individuals, retatrutide produced substantial weight loss and improved glucose levels.

Retatrutide may also benefit non-T2DM individuals seeking weight loss and improved glucose control.

Behavioral interventions and pharmacological therapies may be effective strategies for weight management in PWH.

Integrating behavioral and pharmacological approaches may enhance weight management efforts in PWH.

New glucose-lowering drugs, such as sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, have been confirmed to reduce weight and preserve kidney function.

Clinicians may consider these new drugs as effective treatment options for managing ORG.

Addition of glucagon receptor agonism enhances weight loss, reduces liver fat, and ameliorates dyslipidemia.

Practitioners should consider glucagon receptor agonists for their potential benefits in weight loss and metabolic health.

Liraglutide and semaglutide may provide benefits for weight loss and glycaemic control in people living with HIV.

Practitioners may consider liraglutide and semaglutide for weight management in HIV patients, particularly those with diabetes.

The STEP HFpEF and SELECT trials demonstrated that semaglutide improves clinical outcomes in obese HFpEF patients and reduces cardiovascular and heart failure events in non-diabetic obese patients.

Practitioners should consider semaglutide as a treatment option for improving outcomes in obese HFpEF patients.

GLP-1RA medications are effective in achieving optimal glucose control and reducing all-cause death, cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, and end-stage kidney disease in individuals with type 1 and type 2 diabetes.

GLP-1RA medications can be considered for improving glucose control and reducing serious health risks in diabetic patients.

NuSH-based therapies, including semaglutide and tirzepatide, are highly effective for the treatment of overweight (BMI >27 kg·m−2 with a health condition) and obesity (BMI >30 kg·m−2), with average weight loss exceeding that achieved with lifestyle modification alone.

Healthcare providers should consider prescribing NuSH-based therapies for patients struggling with overweight and obesity.

Chronic use of NuSH-based therapies may improve weight loss in patients who have not responded optimally or have experienced weight recurrence after metabolic/bariatric surgery.

Consider NuSH-based therapies for patients who have struggled with weight loss after surgery.

The FDA has approved GLP-1R agonists, liraglutide and semaglutide, for the management of obesity.

Practitioners can consider GLP-1R agonists as viable pharmacological options for obesity management.

Tirzepatide consistently showed reductions in HbA1c and benefits with weight loss in clinical trials.

Tirzepatide is effective for improving glycemic control and promoting weight loss in type 2 diabetes patients.

Semaglutid is approved in Germany for the treatment of obesity in adults with a BMI of ≥ 30 kg/m2 or ≥ 27 kg/m2 with weight-related comorbidities.

Practitioners can consider Semaglutid as a treatment option for eligible patients with obesity.

Weight loss under Semaglutid therapy can be comparable to bariatric surgical intervention.

Semaglutid may be a viable alternative for patients who are not candidates for surgery.

Tirzepatide achieved up to 20.9% weight loss over 72 weeks in non-diabetic obese individuals.

Tirzepatide can be considered an effective option for weight management in non-diabetic obese patients.

GLP-1 receptor agonists are associated with greater reductions in body weight compared to lifestyle interventions and previous medications.

GLP-1 RAs may be a more effective option for weight loss compared to traditional lifestyle changes.

Tirzepatide (TZP) reduces HbA1c levels by −2.1% compared to insulin lispro U100 added to basal insulin.

TZP may be a more effective treatment option for lowering HbA1c in patients with T2D compared to insulin lispro.

Liraglutide (3.0 mg daily) and semaglutide (2.4 mg weekly) are FDA-approved GLP-1 receptor agonists for weight management.

Practitioners can consider liraglutide and semaglutide as viable options for patients needing weight management.